Top Wall Street Analysts Recommend 3 Dividend Stocks by Mark Eisenberg 25.04.2024 Scotto, Biggar, and Liani rank among top analysts with profitable ratings & impressive average returns, according to TipRanks data. Cisco ...
Is Bank of America Stock a Buy on This Dip? by Mark Eisenberg 25.04.2024 Bank of America faces challenges with interest rates, but business and personal customers continue to trust the bank. Motley Fool ...
Anda Pho: Evite’s New President Transforming Finance by John Darbie 27.03.2024 Evite, after 25 years, gets a much-needed makeover under the leadership of an all-female team targeting moms as their core ...
Barclays Stock Surges Past Key Milestone by Terry Bingman 17.02.2024 Barclays PLC's share price surpasses two hundred day moving average, receiving positive reports from research firms and showing potential for ...
Newmark Boosts UK, Europe Market With Top Hires by Terry Bingman 15.02.2024 Newmark strengthens financial expertise in the UK and Europe with key appointments, signaling its commitment to expansion and enhancing its ...
Bank of America: Trading Surge Amid Net Income Drop by Terry Bingman 14.02.2024 Bank of America reports a decrease in net income but exceeds market expectations with adjusted earnings per share. Trading revenue ...
Evercore Slashes Teradata Target, Maintains Upside by Terry Bingman 13.02.2024 Evercore ISI has adjusted Teradata Corporation's price target to $58 and maintains an Outperform rating despite mixed Q4 results. Teradata's ...
Jefferies Raises Palo Alto Networks Price Target to $450 by Terry Bingman 13.02.2024 Jefferies raises price target for Palo Alto Networks to $450 due to positive evaluation of financial performance, projecting strong growth ...
AI Impact on Jobs: Industry Contradictions by Lilu Anderson 13.02.2024 AI and the future of work brings both opportunities and challenges. While some industries may experience job gains and increased ...
Eli Lilly’s Orfoscerinib: Jefferies Raises Price Target by Mark Eisenberg 13.02.2024 Investment banking firm Jefferies raises Eli Lilly's price target based on optimism over orfoscerinib, indicating strong confidence in its potential. ...